ArticleFrontiers in neurology
HMGB1-TLR4 signaling-mediated neuroinflammation contributes to the pathogenesis of infantile epileptic spasms syndrome in rats.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infantile epileptic spasm syndrome (IESS) is a severe age-dependent epileptic encephalopathy in infancy with poor prognosis and unclear pathogenesis. Neuroinflammation plays a pivotal role in epileptogenesis, and the high-mobility group box 1 protein (HMGB1)-Toll-like receptor 4 (TLR4) axis acts as a core mediator of neuroinflammation. However, its specific role in IESS remains elusive. Objective: This study aimed to explore the HMGB1-TLR4-mediated neuroinflammatory mechanism in a rat model of IESS induced by prenatal stress combined with NMDA, and to evaluate the effects of anti-HMGB1 neutralizing antibody and adrenocorticotropic hormone (ACTH) on epileptic seizures and neuroinflammation, so as to provide novel therapeutic targets for clinical practice. Methods: Pregnant Sprague-Dawley rats were randomly divided into prenatal stress (PS) and non-prenatal stress (NPS) groups. PS rats received cold water immersion and hot air drying, while NPS rats were reared normally. On postnatal day 12 (P12), offspring in the PS group were intraperitoneally injected with NMDA to establish the IESS model, and the NPS group was assigned to blank control (BC) and negative control (NC) subgroups. Model rats were randomly divided into ACTH, anti-HMGB1, ACTH+anti-HMGB1, normal saline, and untreated groups. After intervention on P13, NMDA was re-administered, and seizure latency and severity score were recorded. At the end of the experiment, the expression of HMGB1 and TLR4 in brain tissue was detected, HMGB1 co-localization was observed, and the levels of iNOS, Arg1 and cytokines (IL-1β, IL-2R, IL-8, TNF-α) were measured. Results: Prenatal stress combined with NMDA successfully established a stable IESS model in young rats. The expression of HMGB1, TLR4, iNOS, IL-1β, IL-2R, IL-8 and TNF-α was significantly upregulated, while Arg1 was markedly downregulated. Treatment with ACTH, anti-HMGB1, and their combination prolonged seizure latency, reduced seizure severity, downregulated HMGB1 and TLR4 expression, suppressed HMGB1 levels in neurons, astrocytes and activated microglia, inhibited iNOS and proinflammatory cytokines, and promoted Arg1 expression, with the combined intervention showing the optimal efficacy. Conclusion: Prenatal stress combined with NMDA activates the HMGB1/TLR4 pathway and neuroinflammation in IESS rats. ACTH and anti-HMGB1, alone or in combination, alleviate neuroinflammation by inhibiting this pathway to ameliorate IESS, and the combined therapy yields the best therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.